Ontology highlight
ABSTRACT:
SUBMITTER: Garon EB
PROVIDER: S-EPMC7887048 | biostudies-literature | 2021 Feb
REPOSITORIES: biostudies-literature
Clinical cancer research : an official journal of the American Association for Cancer Research 20201217 4
Both osimertinib and the combination of erlotinib plus ramucirumab are approved for initial therapy of advanced <i>EGFR</i> mutation-positive non-small cell lung cancer. Osimertinib is also approved in previously treated T790M mutation-positive patients. The accompanying article reports on a study combining osimertinib with ramucirumab.<i>See related article by Yu et al., p. 992</i>. ...[more]